On September 21, 2026, the FDA published a major revision to Import Alert 66-80, which covers GLP-1 receptor agonist bulk drug substances (also called active pharmaceutical ingredients, or APIs). If you buy research peptides, this is worth understanding.

What the Alert Does

The alert allows FDA field staff to detain imported GLP-1 APIs without physically examining them. This is called Detention Without Physical Examination, or DWPE. The only exceptions are specific manufacturers and products on the alert’s Green List, which FDA has evaluated and found to appear compliant with current good manufacturing practice (CGMP) requirements.

In practice, this shifts the burden. A shipment from a manufacturer not on the Green List can be held at the border unless the importer shows it meets FDA requirements.

Why FDA Issued It

FDA reviewed 48 GLP-1 API manufacturing sites through inspections and records requests. It found 21% were noncompliant, either because their records showed manufacturing problems or because they did not respond to FDA requests in time. FDA also described a pattern of sites that registered as GLP-1 API manufacturers, offered product for import, declined to provide records, and then deregistered within a short period.

What Changed in This Revision

The September update adds orforglipron to the Green List for several manufacturers and adds new product codes covering general hormone ingredients. The alert already included catch-all codes for general peptides and anti-diabetic ingredients. Taken together, the covered categories now extend well beyond named compounds like semaglutide and tirzepatide.

The Green List also includes one manufacturer in China cleared for retatrutide under specific product codes. FDA does not publish manufacturer names in the public version of the alert.

What This Means for Researchers

This alert targets bulk ingredients entering the United States. It does not directly address individual buyers, but it affects the supply chain many research peptide vendors depend on.

1. Availability may change. Vendors sourcing from manufacturers not on the Green List may face delayed or detained shipments. Expect possible backorders or discontinued items.
2. Pricing may shift. Tighter supply often means higher prices or fewer discounts, even for vendors whose sourcing is unaffected.
3. Documentation matters more. Ask vendors for a certificate of analysis (COA) for the specific lot you receive, and check whether testing was done by an independent third party lab.
4. Be cautious with compliance claims. The public Green List does not name manufacturers, so a vendor claiming its product comes from an FDA approved or Green List source should be able to back that up with documentation.

So, Do We Panic?

No. This is not a ban on research peptides, and it does not target individual buyers. It is a border enforcement tool aimed at bulk ingredients from manufacturers FDA has not cleared. Green List manufacturers can still ship, and many vendors already source from established suppliers.

What it does mean is that the market may get bumpier. Some products may go out of stock for a while, some prices may rise, and some vendors may quietly disappear if their supply depended on sources that can no longer get through. The practical response is not to rush out and stockpile. It is to pay closer attention to who you buy from, ask for lot specific testing, and favor vendors who are transparent about their sourcing.

We will keep our vendor pages and discount codes updated as availability changes. If a code stops working or a product goes out of stock, it may be related to supply disruptions like this one.

This post is for informational purposes only and is not medical or legal advice. Read the full FDA Import Alert 66-80 for complete details.